Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OROruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. (ORKA)

NASDAQ Global Market · Currency in USD
$80.15 ▼ -1.00 (-1.23%)
At close: Oct 23, 4:00 PM ET. Market closed.
$80.15 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$81.15
Open
$80.74
Day's Range
$79.19 – $81.15
52 Week Range
$25.23 – $115.52
Volume
513,993
Avg. Volume
1,102,868
Market Cap
$5.31B
Beta (5Y Monthly)
-0.39
PE Ratio (TTM)
--
EPS (TTM)
-$2.11
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
Aug 29, 2024
1y Target Est
$144.56

Profile: Oruka Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
68
CEO
Lawrence Otto Klein

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.60
DateEst.Actual
Aug 10, 2026-$0.51-$0.55Miss
May 13, 2026-$0.55-$0.48Beat
Mar 12, 2026-$0.61-$0.45Beat
Nov 12, 2025-$0.56-$0.55Beat
Aug 11, 2025-$0.48-$0.46Beat
May 14, 2025-$0.57-$0.40Beat

Analyst view

Consensus price target
$144.56 ▲ +80.4%
Range $120.00 – $200.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ORKA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.